NINTEDANIB ESYLATE
| Brand name | NINTEDANIB ESYLATE |
|---|---|
| Active ingredient | NINTEDANIB ESYLATE |
| Strength | EQ 150MG BASE |
| Dosage form | CAPSULE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | April 2026 |
| Marketing status | RX |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.